Phase II study of @entity2600 combined with XXXX in previously untreated @entity151 .

@entity1 @entity10866 @entity137 @entity2600 @entity66 @entity882 @entity417 @entity5 @entity3003 @entity294 @entity1398 @entity74 @entity151 @entity1210
To determine the efficacy and @entity137 of @entity2600 combined with @entity3003 , we conducted a phase II trial. Eligibility criteria were: chemotherapy-na  ve, @entity151 ( @entity151 ), good performance status (PS: 0-2), age<or=75 years, and adequate organ function. The @entity1 ' characteristics were: male/female=56/5; @entity10866 =19/38/4; median age (range)=68 years(51-75 years); limited disease (LD)/extensive disease ( @entity66 )=27/34. The @entity1 received @entity2600 (50 mg m-2) on days 1, 8, and 15, and @entity3003 (AUC 5, Chatelut formula) on day 1 every 4 weeks. In total, 61 @entity1 were eligible and all were evaluated. In all, 31 @entity1 were treated with four or more courses of chemotherapy. Of the @entity1 , 17 showed a complete response (CR), 34 showed a partial response (PR), nine had @entity66 ( @entity66 ), and one had @entity74 ( @entity74 ). The overall response rate was 84% (95% confidence interval (CI), 72-91%; LD 89%, @entity66 79%) and the CR rate was 28% (95%CI, 17-41%; LD 37%, @entity66 21%). The median time to @entity5 progression was 6.1 (LD 6.4, @entity66 5.4) months. The medial survival time was 15.0 (LD 20.0, @entity66 9.7) months, and the 2-year and 5-year survival rates were 31.1% (LD 48.1%, @entity66 17.7%) and 9.5% (LD 11.1%, @entity66 5.9%), respectively. Grade 3 or 4 @entity1210 , @entity1398 , @entity882 , @entity417 , and @entity294 occurred in 33, 74, 41, 39, and 13% of cases, respectively. In conclusion, the combination of @entity2600 and @entity3003 is an active and well-tolerated regimen in cases of @entity151 .
